SRZN · Surrozen, Inc./DE · Metrics
$27.91
-1.41 (-4.81%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$347.20M
Shares
11.75M
Volume · Oct 5
135.85K
Avg daily vol (3M)
458.99K
SRZN metrics
62 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$29.32
Market cap
$347.20M
Price action
20 metricsPrice change (1W)
-0.7%
Price change (30D)
+41.8%
Price change (3M)
+17.7%
Price change (6M)
+5.2%
Price change (YTD)
+29.7%
Price change (1Y)
+112.9%
Trailing year
Price change (5Y)
—
52-week high
$34.13
52-week low
$11.80
Change from 52-week high
-14.1%
Change from 52-week low
+148.5%
Annualized volatility
132.7%
Annualized volatility (3M)
228.3%
Beta
1.4
RSI (14D)
61.2
Price vs SMA 50
+28.9%
Price vs SMA 200
+19.4%
Avg volume (3M)
458,985
Relative volume
1.4
Average dollar volume
$12.89M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
11.75M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
30.2×
reciprocal yield 3.3%
P / book
—
FCF yield
-10.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-95.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2023-03-22
Profitability
9 metricsGross margin
—
Operating margin
-385.3%
Trailing 12 months
Net margin
-2,885.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$44.35M
Net income (TTM)
−$332.13M
Trailing 12 months
Diluted EPS (TTM)
$-39.55
FCF margin
-303.9%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+408.6%
Year over year
Net income growth YoY
+26.2%
Revenue (TTM)
$11.51M
Trailing 12 months
EPS growth YoY
-116.1%
Shares change YoY
+171.0%
Year over year · more shares
Revenue CAGR (3Y)
-34.7%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-287.3%
Debt / equity
—
Current ratio
12.1
EBITDA (TTM)
−$44.13M
Free cash flow (TTM)
−$34.98M
Quick ratio
12.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$102.04M
Total assets
$115.61M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$34.76M
Capital expenditures (TTM)
$222,000
R&D (TTM)
$34.58M
SG&A (TTM)
—
Stock compensation (TTM)
$7.00M
R&D / revenue
300.4%
Stock compensation / revenue
60.9%
Ownership (13F)
3 metrics13F filers
77
13F filer change QoQ
+8
Institutional ownership
129.5%
Short interest
3 metricsShort interest
18.7%
Latest settlement · 12.7 days to cover
Days to cover
12.7d
Short-squeeze score
86 / 100
Insider activity
2 metricsNet insider buying (90D)
−$6.91M
Insider-sentiment score
21 / 100
Risk flags
1 metricsGoing concern
—